CD276: CD276 antigen
May participate in the regulation of T-cell-mediated immune response.
- Drugs that act on it: 2
- Approved: 0
- In phases 1 to 3: 2
- Sponsors: 2
Who is on it, and how far along
Every drug ChEMBL records acting on CD276, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Antibody 1
- Other 1
| Enoblituzumab | Phase 2 | MacroGenics | Antibody | Cross-linking agentCD276 antigen cross-linking agent | 2 |
| 8H9 131I | Phase 2 | Y-mAbs Therapeutics | Other | Binding agentCD276 antigen binding agent | 0 |
| Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer | Enoblituzumab | Phase 2 | Active, not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Aug 28, 2023 |
| Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer | Enoblituzumab | Phase 2 | Active, not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Oct 4, 2016 |
- Response to statin0.32
- Abnormality of the skeletal system0.29
- Head and neck squamous cell carcinoma0.23
- Prostate cancer0.13
- Cancer0.13
- Non-small cell lung carcinoma0.13
- Triple-negative breast carcinoma0.12
- Pancreatic neoplasm0.12
- Osteosarcoma0.12
- Neuroblastoma0.12
- Neoplasm0.12
- Colorectal carcinoma0.12
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3712879, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q5ZPR3, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets